Jul. 2 at 2:41 PM
$CMMB Still only around a ~
$15M market cap despite trading near
$2.12. In my view, the market is missing the bigger picture.
✅ Positive Phase 2 SPRING data.
✅ FDA alignment on a single pivotal Phase 3 PSC trial.
✅ Recent PSC/IBD analyses showed nebokitug modulated inflammatory and tissue-remodeling pathways relevant to both PSC and IBD. Since roughly 60–70% of PSC patients also have IBD, that could become an important differentiator if confirmed in future studies.
PSC alone is estimated to represent a
$1B+ commercial opportunity, and the Phase 2-ready SSC program is another potential
$1B+ market. Two orphan indications. One first-in-class anti-fibrotic/anti-inflammatory mechanism.
Now ask yourself...what is a company with two potential blockbuster rare-disease opportunities worth if a PSC partnership or SSC licensing deal is announced?
$GILD $TAK $LLY $ABBV
The risks remain, but I believe the risk/reward is among the most compelling in small-cap biotech today. Do your own DD.
